Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02019264
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:13.742462+00:00
Published At
2019-07-16T00:00:00+00:00
Record Updated At
2019-07-16
Results Posted At
2019-07-16
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Cardiovascular Disease", "High Cardiovascular Risk", "Obesity", "Overweight", "Type 2 Diabetes"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-07-16"
protocolSection.identificationModule.nctId
"NCT02019264"
protocolSection.identificationModule.officialTitle
"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2019-07-16"

Study condition terms

  • Cardiovascular Disease (protocolSection.conditionsModule.conditions)
  • High Cardiovascular Risk (protocolSection.conditionsModule.conditions)
  • Obesity (protocolSection.conditionsModule.conditions)
  • Overweight (protocolSection.conditionsModule.conditions)
  • Type 2 Diabetes (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.